Alzheimer’s Drug Controversy Continues As Biogen Publishes Limited Data

Published on March 17, 2022

Biogen Inc on Wednesday published long-awaited results of studies supporting approval of its Alzheimer’s drug in a lesser-known medical journal whose editor was a leader on the research, adding controversy to the already troubled treatment. The data on the drug Aduhelm – the…

Read Full Article (External Site)